VC  Taiwania Capital

     Office Locations:

3945 Freedom Cir #760
Santa Clara, CA 95054
Phone: 886 2 2720 9898
Fax: 886 2 2720 0686



  • Early



  • Communications & Networking
  • Electronics & Advanced Materials
  • Energy & Clean Tech
  • Information Technology
  • Life Sciences & Healthcare



    Taiwania Capital is a venture capital firm that was founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Their mission is to establish a partnership with companies worldwide and boost Taiwan's economic growth. They focus on investing in early-stage companies and have launched two funds during 2017-2018. The key areas are enterprise software, autonomous systems, AI, IoT, robotics & drones, information security, next-gen semiconductors, sensors, and cloud infrastructure. Fund I was launched with a placement which closed at US$150 million. Fund II was launched with a fund size of US$200 million.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Cathy Chen VP
    David Weng CEO
    Huang Lee PhD Managing Partner
    Jerome Shen Ph.D General Partner & Head of Life Science Investments
    Michael Huang Managing Partner


    Recent Funding Events (trailing 12 months):










      Series B


    Portfolio companies include:

        web link

        web link

        web link

        web link

        web link


    Recent News: